BIIB
Biogen Inc
NASDAQ · Biotechnology
$201.18
+15.82 (+8.53%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 9.73B | 10.15B | 3.42B | 3.09B | 3.69B |
| Net Income | 1.64B | 1.54B | 884.71M | 745.08M | 945.00M |
| EPS | — | — | — | — | — |
| Profit Margin | 16.9% | 16.0% | 25.8% | 24.1% | 25.6% |
| Rev Growth | -4.1% | -4.1% | +7.5% | +20.7% | -0.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 4.04B | 4.04B | 13.37B | 12.71B | 12.61B |
| Total Equity | 10.72B | 10.72B | 12.14B | 12.45B | 11.58B |
| D/E Ratio | 0.38 | 0.38 | 1.10 | 1.02 | 1.09 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | 2.88B | 2.85B | 1.31B | 1.15B | 1.28B |
| Free Cash Flow | — | — | 888.62M | 775.19M | 835.69M |